Down 16.65% pre-market: AFX.DE Carl Zeiss Meditec AG (XETRA) guidance in focus
AFX.DE stock plunged 16.65% pre-market to €29.34 after Carl Zeiss Meditec AG reported weak preliminary Q1 results and said full-year guidance is likely under review. The sharp move comes on 3,011,798.00 shares, well above the 180,570.00 average. We see this as a liquidity-driven sell-off tied to guidance risk and currency headwinds.
AFX.DE stock pre-market drop and catalyst
The immediate trigger was a preliminary Q1 report showing revenue of €467.00m versus €490.00m a year ago. Management said preliminary EBITA fell to €8.00m from €35.00m last year. Trading opened at €36.38 and moved to a day low of €28.94, creating heavy intraday volatility.
Fundamentals and valuation for Carl Zeiss Meditec AG (AFX.DE)
Carl Zeiss Meditec AG carries a price to earnings ratio of 18.22 and EPS of €1.61. Market capitalization stands at €2568308558.00. The stock trades below its 50-day average of €41.40 and its 200-day average of €48.25. Price-to-book is 1.21 and price-to-sales is 1.15, which keeps valuation reasonable relative to historical levels.
Technicals and trading signals
Volume spiked to 3,011,798.00 shares, a relative volume of 16.68. The RSI sits at 55.97, indicating neutral momentum after the drop. ADX is 27.13, suggesting a strong trend. Bollinger bands center at €41.12, and the ATR is €1.43, reflecting elevated short-term volatility.
Guidance, news flow and near-term risks
Management warned fiscal 2025/26 guidance will likely not be achieved and will be reviewed. The company pinned the revenue decline on negative currency effects and geopolitical uncertainty. The detailed quarterly statement will be published on 2026-02-12 and management will give an update by the six-month call on 2026-05-12.
Meyka AI grade, price targets and forecast
Meyka AI rates AFX.DE with a score of 68.15 out of 100, Grade B, Suggestion HOLD. This grade factors S&P 500 and sector comparison, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of €50.54, implying a 72.29% upside versus the current €29.34. Forecasts are model-based projections and not guarantees.
We set pragmatic price targets: conservative €28.00, base €40.00, and bullish €52.00. These reflect downside risk near the year low and upside if guidance is restored and currency headwinds fade. All targets assume continued strength in ophthalmic systems demand.
Final Thoughts
AFX.DE stock is trading as a top pre-market loser after preliminary Q1 numbers disappointed the market. The drop to €29.34 reflects a sudden reassessment of guidance and a high volume unwind. Fundamentals remain mixed: a PE of 18.22, book value per share near €24.31, and a dividend yield around 2.04% provide some support. Technical indicators show elevated volatility, and the stock is well below its 50-day and 200-day averages. Meyka AI’s model projects a monthly level of €50.54, implying 72.29% upside from today, but that projection carries material uncertainty. Investors should watch the formal Q1 release on 2026-02-12 and management updates before changing positions. Meyka AI, an AI-powered market analysis platform, flags high short-term risk but recognises potential mid-term upside if guidance is revised upward
FAQs
Why did AFX.DE stock drop pre-market today?
AFX.DE stock fell after preliminary Q1 revenue of €467.00m missed last year and EBITA dropped to €8.00m. Management said fiscal guidance will likely be missed and will be reviewed, driving the pre-market sell-off.
What is the next catalyst for AFX.DE stock?
The next key catalyst is the quarterly statement on 2026-02-12. Management will update guidance and re-organization measures by the six-month call on 2026-05-12.
What price targets and forecast exist for AFX.DE stock?
Meyka AI projects a monthly level of €50.54, implying 72.29% upside versus €29.34. We list targets: conservative €28.00, base €40.00, bullish €52.00. Forecasts are model-based and not guarantees.
Is AFX.DE stock a buy after the drop?
Meyka AI currently rates AFX.DE Grade B with a HOLD suggestion. The stock has reasonable valuation metrics but faces guidance risk. Wait for the official Q1 report and clearer guidance before buying.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
